Poster Abstracts • OFID 2018:5 (Suppl 1) • S459 among 1.9 million hospitalized patients between January 1, 2010 and December 31, 2017. We then reviewed the electronic health records for these patients and collected demographics, clinical characteristics, microbiology, antibiotic treatment, and outcome (30-day mortality).
Background. Ceftolozane-tazobactam (C-T) is a combination antipseudomonal cephalosporin and β-lactamase inhibitor. C-T has been approved in >50 countries for treating adults with complicated urinary tract infections, acute pyelonephritis, and complicated intra-abdominal infections in combination with metronidazole. The Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) monitors C-T resistance among Gram-negative (GN) isolates worldwide. In the current study, isolates were collected from US patients hospitalized with pneumonia (PIHP) from 2015-2017.
Methods. A total of 4,337 GN isolates, including 2,102 Enterobacteriaceae (ENT) and 1,528 Pseudomonas aeruginosa (PSA) isolates, were collected in 2015-2017 from 30 US hospitals and tested for C-T susceptibility (S) by CLSI broth microdilution at JMI Laboratories. Only 1 isolate per patient per infection episode was included. Other antibiotics tested were amikacin (AMK), cefepime (FEP), ceftazidime (CAZ), colistin (COL), levofloxacin (LVX), meropenem (MEM), and piperacillin-tazobactam (TZP).-resistant (R) phenotypes analyzed were ENT R to doripenem, imipenem, or meropenem (CRE) and extended-spectrum β-lactamase (ESBL, non-CRE). Multidrug-resistant (MDR) isolates were identified as nonsusceptible (NS) to 3 or more antimicrobial classes. PSA phenotypes analyzed were CAZ-NS, MEM-NS, and TZP-NS.
Results. Of the 4,337 GN isolates, 3,820 (88.1%) had a C-T MIC ≤8 mg/L. The three most prevalent GN species isolated from PIHP were PSA (n = 1,528; 35.2%), Klebsiella pneumoniae (KPN, n = 562; 13.0%), and Escherichia coli (EC, n = 434; 10.0%). The %S of C-T and comparators for the top 3 pathogens are shown in the table. C-T showed activity against these isolates with %S of 96.5, 88.6, and 97.5% against EC, KPN, and PSA, respectively.
Conclusion. C-T demonstrated activity against the most prevalent contemporary GN isolates from PIHP in the US. C-T was the only β-lactam that had >88%S against all 3 species: EC, KPN, and PSA. C-T and COL were the only agents tested that had >95%S for EC and PSA pathogens in PIHP. For PSA, C-T maintained activity against isolates resistant to CAZ, TZP, and MEM. These data suggest that C-T may be a useful treatment for GN infections causing PIHP. Methods. We conducted a retrospective cohort study using the Truven Health Analytics Commercial Claims and Encounters Database from 2011 to 2016. We identified index case visits for PcP as the point at which a patient was first diagnosed with PcP. We analyzed visits prior to the index diagnosis for symptoms related to PcP; these symptoms included cough, fever, dyspnea, pneumonia or other respiratory infections. We performed a change-point analysis to identify the time window before the index PcP diagnosis where diagnostic opportunities began to appear. We used a simulation model to estimate the likelihood of potential delays representing actual diagnostic opportunities.
Missed and Delayed Diagnosis of Pneumocystis Pneumonia in HIV and Non-HIV-Infected Individuals
Results. In our cohort, we identified 7,656 case patients with PcP, 5,187 in patients with HIV and 2,469 in patients without HIV. We observed a dramatic spike in hospitalizations, ED visits and outpatient visits for symptoms associated with PcP in the period just before the index PcP Diagnosis (see figure) . In the time prior to the index PcP diagnosis, we identified 15,963 visits, and 4,674 patients, with at least one symptom of PcP. Of these potential opportunities, we estimated that 5,396 visits (CI 5, 542) , in 2,868 patients (CI 2,813-2,925), represented likely diagnostic delays. Around 56% of diagnostic opportunities occurred within 14 days of the PcP diagnosis, and 72% occurred within 3 weeks. Diagnostic delays were most likely to occur in outpatient settings: 4,429 outpatient opportunities (CI 4,546-4,679) compared with 674 (CI 706-738) inpatient or ED opportunities. Patients without HIV were more likely to experience a diagnostic delay: 77.4% .2) of non-HIV patients, compared with 18.5% .2) of HIV patients, experienced a delay. Diagnostic delays tended to be longer in patients without HIV, ), compared with patients with HIV, 14.9 days (CI 14.8-15.1).
